Antidepressive effect of an inward rectifier K+ channel blocker peptide, tertiapin-RQ

PLoS One. 2020 Nov 13;15(11):e0233815. doi: 10.1371/journal.pone.0233815. eCollection 2020.

Abstract

Renal outer medullary K+ channel, ROMK (Kir1.1, kcnj1) is expressed in the kidney and brain, but its role in the central nervous system remains unknown. Recent studies suggested an involvement of the ROMK channel in mental diseases. Tertiapin (TPN) is a European honey bee venom peptide and is reported to selectively block the ROMK channel. Here, we have chemically synthesized a series of mutated TPN peptides, including TPN-I8R and -M13Q (TPN-RQ), reported previously, and examined their blocking activity on the ROMK channel. Among 71 peptides tested, TPN-RQ was found to block the ROMK channel most effectively. Whole-cell patch-clamp recordings showed the essential roles of two disulfide bonds and the circular structure for the blockade activity. To examine the central role, we injected TPN-RQ intracerebroventricularly and examined the effects on depression- and anxiety-like behaviors in mice. TPN-RQ showed an antidepressive effect in tail-suspension and forced swim tests. The injection of TPN-RQ also enhanced the anxiety-like behavior in the elevated plus-maze and light/dark box tests and impaired spontaneous motor activities in balance beam and wheel running tests. Administration of TPM-RQ suppressed the anti-c-Fos immunoreactivity in the lateral septum, without affecting immunoreactivity in antidepressant-related nuclei, e.g. the dorsal raphe nucleus and locus coeruleus. TPN-RQ may exert its antidepressive effects through a different mechanism from current drugs.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Antidepressive Agents / pharmacology*
  • Anxiety / drug therapy*
  • Anxiety / pathology
  • Bee Venoms / pharmacology*
  • Behavior, Animal / drug effects*
  • Depression / drug therapy*
  • Depression / pathology
  • Male
  • Mice
  • Mice, Inbred ICR
  • Motor Activity
  • Potassium Channel Blockers / pharmacology*
  • Potassium Channels, Inwardly Rectifying / antagonists & inhibitors*

Substances

  • Antidepressive Agents
  • Bee Venoms
  • Potassium Channel Blockers
  • Potassium Channels, Inwardly Rectifying
  • tertiapin

Grants and funding

M.O. was supported by the KAKENHI (18K06830, 25460323) form JSPS, Wesco Scientific Promotion Foundation, and Ryobi Memorial Foundation. The funders had no role in study design, data collection, analysis, decision to publish, or preparation of the manuscript.